↓ Skip to main content

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus

Overview of attention for article published in Arthritis Research & Therapy, January 2012
Altmetric Badge

Mentioned by

f1000
1 research highlight platform

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
Published in
Arthritis Research & Therapy, January 2012
DOI 10.1186/ar4111
Pubmed ID
Authors

Josefina Cortés-Hernández, Gabriela Ávila, Miquel Vilardell-Tarrés, Josep Ordi-Ros

Abstract

ABSTRACT: INTRODUCTION: Cutaneous lupus erythematosus (CLE) is a chronic disease characterized by disfigurement and a relapsing course. Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal. New thalidomide analogues have been developed but lack clinical experience. The aim of this preliminary phase II study was to evaluate the efficacy and safety of lenalidomide in patients with refractory CLE. METHODS: Fifteen patients with refractory cutaneous lupus disease were enrolled in this single-center, open-label, non-comparative pilot trial between January 2009 and December 2010. Oral lenalidomide (5 to 10 mg/day) was administered and tapered according to clinical response. Patients were followed up for a mean of 15 months (range: 7 to 30). Primary efficacy endpoint was the proportion of patients achieving complete response, defined by a Cutaneous Lupus Erythematosus Disease Area and Severity index (CLASI) activity score of 0. Other secondary endpoints included development of side effects, evaluation of cutaneous and systemic flares, and impact on the immunological parameters. RESULTS: One patient discontinued treatment due to side effects. All remaining patients saw clinical improvement and this was already noticeable after 2 weeks of treatment. Twelve of those patients (86%) achieved complete response but clinical relapse was frequent (75%), usually occurring 2 to 8 weeks after lenalidomide's withdrawal. No influence on systemic disease, immunological parameters or CLASI damage score was observed. Side effects including insomnia, grade 2 neutropenia and gastrointestinal symptoms, were minor (13%). These resolved after withdrawing medication. Neither polyneuropathy nor thrombosis was observed. CONCLUSION: Lenalidomide appears to be efficacious and safe in patients with refractory CLE, but clinical relapse is frequent after its withdrawal. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01408199.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 4%
Spain 2 4%
Unknown 48 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 25%
Other 7 13%
Student > Postgraduate 5 10%
Student > Master 5 10%
Student > Doctoral Student 3 6%
Other 9 17%
Unknown 10 19%
Readers by discipline Count As %
Medicine and Dentistry 23 44%
Immunology and Microbiology 3 6%
Biochemistry, Genetics and Molecular Biology 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Nursing and Health Professions 2 4%
Other 8 15%
Unknown 12 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2013.
All research outputs
#2,018,532
of 3,636,226 outputs
Outputs from Arthritis Research & Therapy
#428
of 816 outputs
Outputs of similar age
#150,739
of 281,269 outputs
Outputs of similar age from Arthritis Research & Therapy
#17
of 35 outputs
Altmetric has tracked 3,636,226 research outputs across all sources so far. This one is in the 26th percentile – i.e., 26% of other outputs scored the same or lower than it.
So far Altmetric has tracked 816 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,269 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.